Inotiv Inc (NOTV) - Total Liabilities

Latest as of December 2025: $625.31 Million USD

Based on the latest financial reports, Inotiv Inc (NOTV) has total liabilities worth $625.31 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NOTV cash generation efficiency to assess how effectively this company generates cash.

Inotiv Inc - Total Liabilities Trend (1997–2025)

This chart illustrates how Inotiv Inc's total liabilities have evolved over time, based on quarterly financial data. See Inotiv Inc shareholders equity for net asset value and shareholders' equity analysis.

Inotiv Inc Competitors by Total Liabilities

The table below lists competitors of Inotiv Inc ranked by their total liabilities.

Company Country Total Liabilities
Kmi Wire And Cable Tbk
JK:KBLI
Indonesia Rp443.81 Billion
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
USA $2.28 Billion
Artemis Resources Ltd
AU:ARV
Australia AU$4.19 Million
Finsbury Growth & Income Trust
LSE:FGT
UK GBX33.77 Million
SL Private Equity
LSE:SLPE
UK GBX229.45 Million
Worksport Ltd
NASDAQ:WKSP
USA $7.84 Million
Atlantis Yatirim Holding AS
IS:ATSYH
Turkey TL23.24 Million
Patriot Resources Ltd
AU:PAT
Australia AU$86.68K

Liability Composition Analysis (1997–2025)

This chart breaks down Inotiv Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Inotiv Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 5.74 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.85 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Inotiv Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Inotiv Inc (1997–2025)

The table below shows the annual total liabilities of Inotiv Inc from 1997 to 2025.

Year Total Liabilities Change
2025-09-30 $635.09 Million +3.97%
2024-09-30 $610.86 Million +3.88%
2023-09-30 $588.04 Million -2.50%
2022-09-30 $603.13 Million +178.29%
2021-09-30 $216.73 Million +301.37%
2020-09-30 $54.00 Million +72.68%
2019-09-30 $31.27 Million +53.40%
2018-09-30 $20.38 Million +70.58%
2017-09-30 $11.95 Million -12.65%
2016-09-30 $13.68 Million +4.46%
2015-09-30 $13.10 Million -8.01%
2014-09-30 $14.24 Million -11.77%
2013-09-30 $16.14 Million -7.17%
2012-09-30 $17.39 Million +3.73%
2011-09-30 $16.76 Million -12.14%
2010-09-30 $19.08 Million -2.00%
2009-09-30 $19.46 Million -13.69%
2008-09-30 $22.55 Million -3.96%
2007-09-30 $23.48 Million -5.92%
2006-09-30 $24.96 Million -11.62%
2005-09-30 $28.24 Million +3.16%
2004-09-30 $27.38 Million +8.38%
2003-09-30 $25.26 Million +73.43%
2002-09-30 $14.56 Million +43.54%
2001-09-30 $10.15 Million -4.29%
2000-09-30 $10.60 Million +19.11%
1999-09-30 $8.90 Million +61.82%
1998-09-30 $5.50 Million -38.89%
1997-09-30 $9.00 Million --

About Inotiv Inc

NASDAQ:NOTV USA Diagnostics & Research
Market Cap
$10.66 Million
Market Cap Rank
#26727 Global
#5326 in USA
Share Price
$0.31
Change (1 day)
+6.86%
52-Week Range
$0.23 - $3.01
All Time High
$57.88
About

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more